DF/HCC New Member

Please welcome Dr. Wander who recently joined DF/HCC and is a member of Breast Cancer and Cancer Genetics Programs

Transcript:

My name is doctor Seth Wander. I am a faculty member at Massachusetts General Hospital in the division of medical oncology. My interest is in breast cancer and cancer genomics and I recently joined the DF/HCC in those areas.

My clinical and research interests are in molecular mechanisms of resistance to targeted therapy and metastatic hormone receptor-positive breast cancer. For the last several years I have been collaborating with Dr. Nikhil Wagle at Dana-Farber and looking at new genomic mechanisms of resistance to cyclin CDK for six inhibitors in ER-positive breast cancer. We have a dedicated computational and research effort in the space and are excited to be expanding into a number of different areas past this.

We’re always interested in new collaborations. We are very interested in thinking about deploying novel sequencing technologies and patient samples from metastatic breast cancer. We are also interested in new molecular and xenograft models that might help to explore mechanisms of resistance that we can identify via patient sequencing.